{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:45:38Z","timestamp":1790660738522,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A key component of global tuberculosis (TB) control is the treatment of latent TB infection. The use of long-acting technologies to administer TB preventive treatment has the potential to significantly improve the delivery and impact of this important public health intervention. For example, an ideal long-acting treatment could consist of a single dose that could be administered in the clinic (ie, a \u201c1-shot cure\u201d for latent TB). Interest in long-acting formulations for TB preventive therapy has gained considerable traction in recent years. This article presents an overview of the specific considerations and current preclinical advancements relevant for the development of long-acting technologies of TB drugs for treatment of latent infection, including attributes of target product profiles, suitability of drugs for long-acting formulations, ongoing research efforts, and translation to clinical studies.<\/jats:p>","DOI":"10.1093\/cid\/ciac672","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T21:43:38Z","timestamp":1669067018000},"page":"S510-S516","source":"Crossref","is-referenced-by-count":13,"title":["Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment"],"prefix":"10.1093","volume":"75","author":[{"given":"Nicole C","family":"Ammerman","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, University Medical Center Rotterdam, Erasmus MC , Rotterdam , The Netherlands"},{"name":"Center for Tuberculosis Research, The Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, The Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Long-acting Therapeutics, University of Liverpool , Liverpool , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve P","family":"Rannard","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Long-acting Therapeutics, University of Liverpool , Liverpool , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caren Freel","family":"Meyers","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"2023053018552269400_ciac672-B1","author":"World Health Organization"},{"key":"2023053018552269400_ciac672-B2","author":"World Health Organization"},{"key":"2023053018552269400_ciac672-B3","author":"United Nations General Assembly 73\/3"},{"key":"2023053018552269400_ciac672-B4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis","volume":"12","author":"Balcells","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2023053018552269400_ciac672-B5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.5588\/ijtld.15.0908","article-title":"Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis","volume":"20","author":"den Boon","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023053018552269400_ciac672-B6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/COH.0000000000000376","article-title":"Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings","volume":"12","author":"Maartens","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2023053018552269400_ciac672-B7","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023053018552269400_ciac672-B8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2023053018552269400_ciac672-B9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2023053018552269400_ciac672-B10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5588\/ijtld.17.0486","article-title":"Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges","volume":"22","author":"Swindells","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023053018552269400_ciac672-B11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5588\/ijtld.21.0667","article-title":"WHO Target product profiles for TB preventive treatment","volume":"26","author":"Den Boon","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023053018552269400_ciac672-B12","author":"World Health Organization"},{"key":"2023053018552269400_ciac672-B13","author":"World Health Organization"},{"key":"2023053018552269400_ciac672-B14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1513\/AnnalsATS.201905-394OC","article-title":"Temporal factors and missed doses of tuberculosis treatment. A causal associations approach to analyses of digital adherence data","volume":"17","author":"Stagg","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2023053018552269400_ciac672-B15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.5588\/ijtld.17.0515","article-title":"Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study","volume":"22","author":"Rajoli","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023053018552269400_ciac672-B16","first-page":"10","article-title":"Comparing injection site pain with paliperidone palmitate versus first-generation depot antipsychotics in subjects with schizophrenia","volume":"12","author":"Gopal","year":"2015","journal-title":"Innov Clin Neurosci"},{"key":"2023053018552269400_ciac672-B17","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1096\/fj.14-255786","article-title":"Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes","volume":"28","author":"Edagwa","year":"2014","journal-title":"FASEB J"},{"key":"2023053018552269400_ciac672-B18","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.2147\/IJN.S163925","article-title":"Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against Mycobacterium tuberculosis H37Rv strain","volume":"13","author":"Hakkimane","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"2023053018552269400_ciac672-B19","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1002\/smll.201500937","article-title":"pH-responsive isoniazid-loaded nanoparticles markedly improve Tuberculosis treatment in mice","volume":"11","author":"Hwang","year":"2015","journal-title":"Small"},{"key":"2023053018552269400_ciac672-B20","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1021\/acs.biomac.1c00554","article-title":"Dual pH-responsive macrophage-targeted isoniazid glycoparticles for intracellular tuberculosis therapy","volume":"22","author":"Lunn","year":"2021","journal-title":"Biomacromolecules"},{"key":"2023053018552269400_ciac672-B21","doi-asserted-by":"crossref","first-page":"e00007-19","DOI":"10.1128\/AAC.00007-19","article-title":"Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053018552269400_ciac672-B22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1164\/rccm.202012-4541OC","article-title":"Efficacy of long-acting bedaquiline regimens in a mouse model of tuberculosis preventive therapy","volume":"205","author":"Kaushik","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2023053018552269400_ciac672-B23","author":"Spreen"},{"key":"2023053018552269400_ciac672-B24","author":"Li"},{"key":"2023053018552269400_ciac672-B25","author":"Nuermberger"},{"key":"2023053018552269400_ciac672-B26","author":"Kim"},{"key":"2023053018552269400_ciac672-B27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jinf.2020.09.032","article-title":"Mycobacterium tuberculosis-specific cytokine biomarkers to differentiate active TB and LTBI: a systematic review","volume":"81","author":"Sudbury","year":"2020","journal-title":"J Infect"},{"key":"2023053018552269400_ciac672-B28","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TBTB2-0034-2017","article-title":"Preclinical efficacy testing of new drug candidates","volume":"5","author":"Nuermberger","year":"2017","journal-title":"Microbiol Spectr"},{"key":"2023053018552269400_ciac672-B29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev-pharmtox-030920-011143","article-title":"Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis","volume":"61","author":"Ernest","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2023053018552269400_ciac672-B30","doi-asserted-by":"crossref","first-page":"e0170521","DOI":"10.1128\/AAC.01705-21","article-title":"Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modeling study","volume":"65","author":"Radtke","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053018552269400_ciac672-B31","author":"Farenc"},{"key":"2023053018552269400_ciac672-B32","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"2023053018552269400_ciac672-B33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023053018552269400_ciac672-B34"},{"key":"2023053018552269400_ciac672-B35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS clinical trials group A5221 STRIDE study","volume":"57","author":"Luetkemeyer","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023053018552269400_ciac672-B36","first-page":"549","article-title":"Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023053018552269400_ciac672-B37","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/civ477","article-title":"Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy","volume":"61","author":"Taburet","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023053018552269400_ciac672-B38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023053018552269400_ciac672-B39","author":"Imperial"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_4\/S510\/50491158\/ciac672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_4\/S510\/50491158\/ciac672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T18:56:10Z","timestamp":1685472970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/Supplement_4\/S510\/6835720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":39,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2022,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac672","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,11,21]]}}}